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Aims Low androgen levels have been linked with an increased risk of cardiovascular disease in men. Previous studies have sug-
gested that androgens directly inhibit atherosclerotic lesion formation although the underlying mechanisms for this
remain unclear. This study addressed the hypothesis that endogenous androgens inhibit arterial remodelling by a
direct action on the androgen receptor (AR) in the vascular wall.
Methods
and results
We studied a series of novel mouse lines with cell-specific deletion of the AR in either the endothelium or in smooth
muscle cells or both cell types. Findings were compared with a model of global androgen deficiency in wild-type mice
(castrated). We characterized the cardiovascular phenotype, vascular pharmacology and histology, and assessed neoin-
timal lesion formation following vascular injury to the femoral artery. Cell-specific AR deletion did not alter body weight,
circulating testosterone levels or seminal vesicle weight, but caused limited alterations in arterial contractility and blood
pressure. Neointimal lesion formation was unaltered by selective deletion of AR from the vascular endothelium, smooth
muscle, or both cell types. Castration in wild-type mice increased neointimal lesion volume (Sham vs. Castration:
2.4 × 107+4.5 × 106 vs. 3.9 × 107+4.9 × 106 mm3, P ¼ 0.04, n ¼ 9–10).
Conclusion Vascular cell-specific AR deletion had no effect on neointimal lesion formation, while low systemic androgen levels ad-
versely affect neointimal lesion size. These findings suggest that the cardio-protective effects of androgens are mediated
either by AR outside the vasculature or by AR-independent mechanisms.
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1. Introduction
Male sex hormones have traditionally been linked to the greater risk of
cardiovascular disease (CVD) in men.1,2 However, this view is increas-
ingly being challenged, with considerable recent evidence that testoster-
one may, in fact, be cardio-protective. Cross-sectional studies have
associated low testosterone levels with increased cardiovascular risk
factors (diabetes mellitus, the metabolic syndrome, abnormal lipid
profile) and increased cardiovascular risk in men.2– 5 This is particularly
important given the progressive population-level decline in serum tes-
tosterone concentrations in men from developed countries6 –8 which
has resulted in a dramatic increase in the use of androgen replacement
therapy (ART). Indeed, there has been a 10-fold increase in prescribed
ART in the USA9 and nearly a 3-fold increase in the UK10 in the past
decade. ART improves the muscle/fat mass ratio, bone mineral
density, and blood lipid profile6,11,12 in hypogonadal men. It has also
been suggested that ART could provide a novel strategy to reduce car-
diovascular risk. More recently, however, concerns have been raised
about safety and the Food and Drug Administration in the USA has
announced an investigation into the risk of stroke, heart attack, and
death in men taking testosterone products.13 This follows recent
reports demonstrating an excess of cardiovascular events in apparently
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hypogonadal men using ART.14–16 Given the inconsistent findings
from clinical studies, there is a clear need for additional pre-clinical
studies to improve our understanding of how endogenous androgens
and pharmacological androgen supplements influence CVD. Previous
pre-clinical studies have focused on pharmacological testosterone sup-
plementation and/or deficiency (by castration) and have largely sup-
ported a cardio-protective role for androgens, with pharmacological
testosterone replacement in castrated animals reducing atherosclerotic
plaque formation.17– 19 However, the mechanism of this effect is not
clear. It may be indirect, following modification of conventional cardio-
vascular risk factors, and/or due to direct modulation of vascular remod-
elling. Furthermore, it has not been established whether androgens alter
vascular remodelling by direct stimulation of the androgen receptor
(AR), by testosterone-mediated AR-independent actions, or, indirectly,
via aromatase-mediated conversion of testosterone to oestrogens.
In models of arterial injury that lack elevated systemic cardiovascular
risk factors, the findings are contradictory, with studies showing that
androgens either reduce20 (possibly by inhibiting arterial smooth muscle
proliferation),21 or have no effect on22 neointimal lesion formation.
Endogenous androgens play a complex role in determining cardiovas-
cular risk and thus investigation of their mechanism of action is challen-
ging. The influence of AR stimulation on vascular lesion formation has
been investigated previously using the testicular feminised (Tfm)
mouse, which lacks a functional AR.19 However, interpretation of
results from this animal is confounded by the fact that it lacks AR in
all tissues, has low (10%) circulating testosterone, and, consequently,
has sub-physiological concentrations of oestradiol. Generation of a
similar total AR knockout mouse on an atherosclerosis-prone (apoE2/2)
background suggested that androgens reduce total serum cholesterol
via an AR-dependent mechanism but implicated both AR-dependent
and AR-independent mechanisms in the observed anti-atherosclerotic
effects.23 Recognizing the limitations of these models and the complex
role of androgens in influencing a number of aspects of cardiovascular
risk, we generated mice with vascular cell-specific deletions of AR in
order to address the hypothesis that endogenous testosterone inhibits
neointimal proliferation by stimulation of AR in the vascular wall.
2. Methods
SeeSupplementarymaterial, OnlineData fordetailed materials andmethods
related to this study.
2.1 Mice
Animal experiments were performed in accordance both with Directive
2010/63/EU of the European Parliament and with the UK Home Office
Animal (Scientific Procedures) Act 1986.
C57Bl/6J mice were supplied by the University of Edinburgh Biomedical
Research Facility. Mice with selective ablation of AR from vascular endothe-
lial (VE-ARKO)24 or smooth muscle cells (SM-ARKO)25 were established in
our laboratory as previously described. In this study, these two lines were
mated to generate stud males hemizygous for both Tie2-Cre and SM22-Cre,
which were then mated with female ARfl/fl mice. The mouse line was main-
tained by breeding male SM22-Cre+/2:Tie2-Cre+/2:ARfl/y mice with female
ARfl/fl mice. Four genotypes were identified in the resultant offspring at
expected Mendelian ratios (25% for each genotype in male pups):
(1) WT: SM22-Cre2/2:Tie2-Cre2/2:ARfl/y. Used as controls.
(2) SM-ARKO: SM22-Cre+/2:Tie2-Cre2/2:ARfl/y. Smooth muscle cell
(SMC) ARKO.
(3) VE-ARKO: SM22-Cre2/2:Tie2-Cre+/2:ARfl/y. Endothelial cell (EC)
ARKO.
(4) SM/VE-ARKO: SM22-Cre+/2:Tie2-Cre+/2:ARfl/y. Smooth muscle
and EC double ARKO.
In this study, only male mice were used for onward analysis.
2.2 Determination of genomic ablation of AR
and genotyping of mice
To verify AR ablation in target cells, genomic DNA was extracted immedi-
ately from freshly isolated aortic EC and SMC cells (without any culturing)
and subjected to PCR amplification using primers GCTGATCATAGGCC
TCTCTC and TGCCCTGAAAGCAGTCCTCT. An amplicon of 1142 bp
indicated the presence of a floxed AR, while an amplicon of 612 bp indicated
recombination between loxP sites and deletion of AR exon 2.24
Inheritance of Cre Recombinase was used to determine genotype.
Genomic DNA from ear clips was amplified using primers CGCATAAC
CAGTGAAACAGCATTGC and CCCTGTGCTCAGACAGAAATGAGA
for Tie2-cre;26 and CGCATAACCAGTGAAACAGCATTGC and CAGA
CACCGAAGCTACTCTCCTTCC for SM22-cre.27 An amplicon of 608 bp
indicated the inheritance of the Cre Recombinase transgene in EC under
controlof theTie2promoter, while an ampliconof575 bp for theCreRecom-
binase transgene in SMC under control of SM22 promoter.
2.3 Vascular cell isolation and culture
Mice were euthanized by CO2 and aortic EC and SMC isolated, by collage-
nase digestion, and cultured, as described.28 Isolated cells were either
used directly for DNA extraction, or cultured (EC, 7 days in endothelial
culture medium; SMC, 14 days in DMEM/F12 GlutaMAXTM) for investigation
of AR expression. Testosterone (1 × 1027 M), DHT (1 × 1028 M), or
vehicle (100% ethanol, 0.1% in final culture medium) was added from the
3rd day of culture and media were replenished twice weekly.
2.4 Phenotyping mice with cell-specific AR
deletion
2.4.1 Blood pressure measurement
Systolic blood pressure was assessed in conscious, restrained mice using
tail-cuff plethysmography (Harvard Apparatus, UK).
2.4.2 Assay for plasma testosterone, total cholesterol,
and triglyceride
Plasma testosterone (DEMEDITEC Diagnostics GmbH, Kiel-Wellsee,
Germany), total plasma cholesterol (Olympus Diagnostics Ltd, Watford,
UK), and plasma triglyceride (Alpha Laboratories Ltd., Eastleigh, UK) were
measured using commercially available kits, in accordance with manufac-
turer’s instructions.
2.4.3 Myographic assessment of arterial function
Mice (12–16 weeks) were euthanized by CO2. Femoral and mesenteric ar-
teries were isolated for functional analysis, as described previously.29 A linear
relationship between the increment of cyclic force and the increment of
diameter was used to describe arterial compliance.30 Arteries were then
exposed to high (125 mM) potassium physiological saline solution (KPSS),
phenylephrine (PhE, 1029–1025 M), acetylcholine (ACh; 1029–1025 M),
and sodium nitroprusside (SNP; 1029–1025 M). A further set of arteries
from the same animals were exposed to testosterone (1029–1024 M) and
endothelin-1 (ET-1, 10211–1027 M).
2.5 Surgical procedures
Surgical procedures were performed in mice under isoflurane-induced an-
aesthesia with analgesic cover.
2.6 Castration
In C57Bl/6J mice, a small incision wasmade in the mid-line of the scrotum and
both testes externalized and removed (castration) or returned to the
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scrotum (Sham). The mice were allowed to recover for 1 week prior to in-
duction of femoral artery injury.
2.7 Femoral artery injury
Wire injury was performed by inserting a guidewire using the method of Sata
et al.31 Ligation injury was performed on the common femoral artery imme-
diately proximal to the femoropopliteal bifurcation. Wounds were sutured
and mice were allowed to recover (21 days) to allow lesion development.
2.8 Optical projection tomography (OPT)
Mice were killed (sodium pentobarbital) and plasma harvested and stored
(2208C). Mice were then perfusion-fixed, femoral arteries excised from
the femoropopliteal branch to the bifurcation with the iliac artery, and
then processed for optical projection tomography (OPT), as described.32
Longitudinal lesion distribution and total neointimal volume in the first
1.2 mm segment of the artery were used to describe the overall neointima
formation (Supplementary material online, Figure S1). The maximum cross-
sectional neointimal area was determined from serial histological sections
indicated the level of stenosis (Supplementary material online, Figure S1).
2.9 Histology and immuno-fluorescent staining
After OPT scanning, tissues were processed for histology, sectioned (5 mm)
and stained with Masson’s trichrome. Intimal and luminal area were mea-
sured using Image Pro Plus 7.0 rom images obtained using a CoolSNAP
camera (Photometrics, UK). Immuno-florescent staining was with Tyramide
Signal Amplification (TSATM, PerkinElmer) was applied using primary
Figure1 Identificationof AR in murine vascular cells. AR is expressed in EC (redarrows) and SMC (green arrows) in healthy mouse aorta (A). The dashed
yellow line indicates the external elastic lamina. AR expression was up-regulated by testosterone (1× 1027 M) in cultured mouse aortic EC (B) and SMC (C).
EC were identified using antibodies against vWF and CD31; SMCs were identified using an antibody against SMA. Nuclei were counter-stained with DAPI.
AR in vascular injury 283
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antibodies against: AR (SantaCruz; 1:400), CD31 (Abcam; 1:300), von
Willebrand factor (vWF, Dako; 1:2000), and smooth muscle alpha-actin
(SMA, Sigma; 1:1000). Fluorescent images were analysed using confocal
microscopy.
For cultured cells, samples were fixed, stained without antigen retrieval,
and images were captured using a Zeiss Axiovert 200M epi-fluorescent
microscope (Carl Zeiss Ltd., Welwyn, UK).
2.10 Statistics
Data are mean+ standard error of the mean (SEM) for n mice, unless indi-
cated otherwise. Analysis was performed (GraphPad Prism v5.0) using Stu-
dent’s t-test, one-way or two-way ANOVA with a Bonferroni post-hoc test,
as appropriate; P, 0.05 indicated statistical significance.
3. Results
3.1 AR localization in vascular tissues
Immunohistochemistry confirmed AR expression in intact mouse aorta
(Figure 1A) and in cultured aortic EC (Figure 1B) and SMC (Figure 1C).
AR expression in mouse aortic EC and SMC was increased following
incubation with testosterone (1 × 1027 M) (Figure 1B and C ).
3.2 Establishment of vascular cell-specific
AR knockout mice (ARKO)
Three vascular cell-specific AR-ablated mice were generated using the
cre-loxP system; SM-ARKO (smooth muscle ARKO, generated using
SM22-Cre), VE-ARKO (EC ARKO, generated using Tie2-Cre), and
SM/VE-ARKO (smooth muscle and ECs, generated from inter-crossing
both Cre lines), and floxed-AR mice (WT), which were used as controls.
In order to confirm deletion of AR in targeted cell types, genomic
DNA from freshly isolated aortic EC and SMC were subjected to PCR
analysis. An 1142 bp band representing the wild-type AR allele was
only observed in WT EC and SMC, SM-ARKO EC and VE-ARKO
SMC (Figure 2A). A recombined 612 bp band representing the recom-
bined non-functional AR allele was only observed in SM-ARKO SMC,
VE-ARKO EC, and SM/VE-ARKO EC/SMC. Genomic DNA samples iso-
lated from ear biopsies were used for genotyping. The SM22-cre ampli-
con consistently correlated with AR ablation in SMC and the Tie2-cre
amplicon with AR ablation in EC (Figure 2B).
3.3 Characterization of SM-ARKO/
VE-ARKO and SM/VE-ARKOmice
Mice of all four genotypes were healthy. In contrast to Tfm or global
ARKO mice,19,23 SM-ARKO, VE-ARKO, and SM/VE-ARKO mice had
normal circulating testosterone concentrations (Figure 2C) and seminal
vesicle weights (Figure 2D). Total plasma cholesterol and triglyceride
were not affected by vascular ARKO (Supplementary material online,
Figure S2). Tail-cuff plethysmography revealed a small but significant
increase in blood pressure in VE-ARKO mice (Figure 2E).
Ex vivo myography was used to determine whether vascular AR dele-
tion was associated with functional changes in smooth muscle contrac-
tionorendothelium-dependent relaxation.VascularARdeletion didnot
Figure 2 Characterization of mice with vascular cell-specific AR deletion. Cell-specific AR deletion was confirmed (A; n ¼ 4 for each genotype) using
PCRon genomic DNA from freshly isolated aortic EC and SMC. Mouse genotypes were confirmed (B) with PCR using genomic DNA fromear clip samples.
Deletion of vascular AR did not alter circulating testosterone levels (C; n ¼ 14–23) or seminal vesicle weight (D; n ¼ 8–15) but deletion of AR from
EC (VE-ARKO) produced a small increase in systolic blood pressure (E). *P, 0.05 (n ¼ 7–12) by one-way ANOVA plus Bonferroni post-hoc test.
(WT ¼ wild-type litter mates carrying floxed-AR; SM-ARKO ¼ AR ablated in SMC, VE-ARKO ¼ AR ablated in EC, SM/VE-ARKO ¼ AR ablated in
both EC and SMC.)
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alter femoral or mesenteric arterial compliance (Supplementary mater-
ial online, Figure S3). PhE-induced contraction, however, was reduced in
femoral arteries that lack smooth muscle cell AR from both SM-ARKO
and SM/VE-ARKO mice (Figure 3A), while there was a small reduction in
ET-1 mediated contraction in all vascular ARKOs (Figure 3B). Vascular
AR ablation did not alter PhE- (Figure 3C) or ET-induced (Figure 3D) con-
striction in mesenteric arteries. KPSS-induced receptor-independent
constriction (Supplementary material online, Figure S4A(i) and B(i)),
ACh-induced endothelium-mediated dilation (Figure 3E and F ), and
SNP-induced endothelium-independent dilation (Supplementary material
online, Figure S4A(ii) and B(ii)) were not affected by vascular ARKO.
Testosterone-induced dilation, which occurred at supra-physiological
concentrations (1 × 1024 M), showedno dramatic alterations following
deletion of AR from vascular EC and/or SMC, despite some small
differences in response at specific concentrations (Figure 4).
3.4 Influence of castration on neointimal
lesion formation
Castration reduced circulating testosterone concentrations (Figure 5A)
and seminal vesicle weight (Figure 5B) and decreased AR expression in
femoral arteries (Figure 5C). Body weights following surgery were
lower in castrated mice than in controls (Supplementary material
online, Figure S5). Castration also increased neointimal lesion formation
following wire injury (Figure 6A), resulting in increased lesion volume but
without increasing the maximal cross-sectional area. In contrast, castra-
tion had no effect on the neointimal lesion formation following arterial
ligation (Figure 6B).
3.5 Effect of vascular ARKO on neointimal
lesion formation
Body-weight changes after arterial injury were similar among the four
genotypes of mice (Supplementary material online, Figure S6). Vascular
ARKO did not alter the profile (Figure 7A(i)), volume (Figure 7A(ii)),
or cross-sectional area (Figure 7A(iii)) of lesions induced following
wire injury. Similarly, SM-ARKO and SM/VE-ARKO had no effect on
lesion size following arterial ligation (Figure 7B). In contrast, deletion
of AR from vascular ECs alone (VE-ARKO) resulted in an altered
lesion profile (Figure 7B(i)) and a small increase in lesion volume
(Figure 7B(ii)), but not cross-sectional area (Figure 7B(iii)), following
ligation.
Figure 3 Agonist-dependent vascular dysfunction in mice with selective deletion of vascular AR. In isolated femoral (A, B, E) and mesenteric (C, D, F )
arteries cumulative concentration-response curves were produced using phenylephrine (PhE; A and C) or endothelin-1 (ET-1; B and D). Acetylcholine
(ACh; E and F) induced-relaxation was obtained after contraction with a sub-maximal concentration of PhE (3 × 1026 M). $$P, 0.01 vs. WT;
*P, 0.05, **P, 0.01 vs. corresponding WT concentration; #P, 0.05, ##P, 0.01 vs. corresponding VE-ARKO concentration; two-way ANOVA with
the Bonferroni post-hoc test. (WT ¼ wild-type litter mates carrying floxed-AR; SM-ARKO ¼ AR ablated in SMC, VE-ARKO ¼ AR ablated in EC, SM/
VE-ARKO ¼ AR ablated in both EC and SMC. n ¼ 5–9.)
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4. Discussion
Declining testosterone levels in men, combined with increased
ART, may both have an impact on the development of CVD possibly
by affecting the development of atherosclerotic lesions. Precisely how
endogenous androgens influence the formation of vascular lesions
remains unknown. This investigation addressed the hypothesis that
androgen-induced stimulation of AR in the vascular wall inhibits neonti-
mal lesion development. This was addressed using a series of novel
vascular-cell-specific mouse lines with AR deleted from EC and/or
SMC. Cell-specific deletion of vascular AR did not alter neointimal
lesion formation, while castration in wild-type mice did result in
adverse neointimal lesion formation. These contrasting findings
suggest that the effects of androgens on vascular lesion formation are
mediated by one or more of the following mechanisms: (i) activation
of AR-independent pathways, (ii) secondary to aromatization of andro-
gen to oestrogen, (iii) stimulation of AR in other cell types.
The generation of vascular-specific ARKO mice was central to this in-
vestigation. The functional role of AR has been investigated previously
using Tfm19 mice. Interpretation of data from these animals is compli-
cated, however, by low endogenous levels of testosterone and oestra-
diol (requiring pharmacological replacement). In contrast, consistent
with previous demonstrations,22,23 vascular cell-specific deletion of
AR did not reduce circulating testosterone levels and, therefore, no ex-
ogenous androgen administration was required. This is important since
pharmacological administration of androgens does not satisfactorily
‘replace’ endogenous hormone. The pharmacokinetics and tissue accu-
mulation of pharmacologically administered androgen are not fully
understood (thus overdosing may occur if the serum/plasma testoster-
one level is the only clinical parameter for androgen prescription). This
mayexplain (i) the unexpected increase in adverse cardiovascularevents
associated with androgen treated in a clinical trial involving elderly (.65
years old) hypogonadal men,16 and (ii) the increased death and incidence
of stroke and myocardial infarction (regardless of the pre-existing CVD)
associated with clinical androgen replacement in hypogonadal men, as
demonstrated in a large scale observational study.14
Androgens contribute to elevation of blood pressure by acting on
catecholamines in the brain, independent of classical AR; blood pressure
Figure 4 Testosterone induces relaxation in vascular ARKO arteries. Supra-physiological concentration of testosterone induced vascular relaxation
both in femoral (A) and mesenteric (B) arteries from all genotypes, which was independent of the type of pre-constriction. Vascular ARKO produced
no dramatic changes in testosterone-mediated relaxation despite some small differences in relaxation at specific concentrations. *P, 0.05, **P, 0.01
vs. corresponding WT concentration; #P, 0.05 vs. corresponding VE-ARKO concentration; two-way ANOVA plus Bonferroni post-hoc test.
(WT ¼ wild-type litter mates carrying floxed-AR; SM-ARKO ¼ AR ablated in SMC, VE-ARKO ¼ AR ablated in EC, SM/VE-ARKO ¼ AR ablated in
both EC and SMC. n ¼ 7–9.)
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in wild-type and Tfm rats is reduced by castration and restored by admin-
istration of testosterone.33 This contrasts with vascular selective ARKO
which showed either no change or, in the case of VE-ARKO, a small
elevation in blood pressure. The implication, therefore, is that
testosterone-mediated elevation of blood pressure is not mediated by
vascular AR. The increased blood pressure in VE-ARKO mice suggests
slight EC dysfunction, but this was not supported by our findings in iso-
lated arteries.
Disruption of systemic androgen/AR signalling impairs normal vascu-
lar function.34 In Tfm mice, contraction in response to high potassium
(but not to noradrenaline) was reduced in femoral arteries, suggest-
ing altered smooth muscle cell function.34 Relaxation in response
to ACh was also impaired, suggesting EC dysfunction.34 Vascular AR
ablation had no effect on passive arterial compliance and did not
alter endothelium-dependent or -independent relaxation, confirming
normal activity of the endothelium-derived nitric oxide system. It was
notable that EC function was maintained in VE-ARKO mice, despite
the (small) increase in blood pressure in these animals. Unlike the Tfm,
smooth muscle AR deletion impaired agonist-mediated contraction
without altering the response to potassium, suggesting a change in
receptor-dependent signal transduction pathways. Reduced contraction
was agonist dependent (being more evident in response to noradrenaline
than to ET-1) and tissue-specific (more obvious in the femoral, than in the
mesenteric, artery). An androgen-mediated alteration of adrenoceptor
activation would be consistent with androgen-induced production and
release of noradrenaline in rodents.35 The differences between the
current results and those reported for Tfm suggest that AR expressed
outside the vasculature contributes to regulation of vascular function.
The lowtestosterone inTfmcouldalso leadtoa lossof rapid, non-genomic
androgen signalling. Alternatively, since endogenous oestrogen regulates
EC function in males,36,37 the impaired endothelium-mediated dilation
in the Tfm mice could be a result of its low oestrogen levels.
As shown previously,38 testosterone caused relaxation of arteries, al-
though only at supra-physiological concentrations. The maintenance of
this response in the vascular-specific ARKO mice is consistent with data
from Tfm mice.34 This indicates, therefore, that vascular AR does not
mediate this response. Similar arterial relaxation has been observed
with high concentrations (≥1 × 1024 M) of corticosteroids, oestrogen,
and cholesterol39,40 and may be due to direct alteration of the cell mem-
brane. Given the very high concentrations required to produce this re-
sponse, testosterone-induced vasodilation is very unlikely to have any
physiological relevance.
Evidence for androgen-mediated inhibition of vascular neointimal
lesion formation under normolipidemic conditions is less conclusive
than for inhibition of atherosclerosis.20,22 This investigation addressed
the influence of androgens/AR on neointimal lesion formation using
models of denuding (wire) and non-denuding (ligation)41 injury. Wire
injury denudes the endothelium and produces lesions formed predom-
inantly from circulating bone marrow-derived progenitor cells. On the
other hand, femoral artery ligation does not introduce direct endothelial
damage. The disturbed blood flow and altered shear stress may induce
endothelial dysfunction and stimulate neointima formation by migration
Figure 5 Castration reduces vascular AR expression. Plasma testosterone concentrations (A), seminal vesicle weight (B), and AR expression in lesion-
bearing femoral arteries (C ) were reduced following castration. **P, 0.01. Data were analysed by Student’s t-test. (A: n ¼ 9–11; B: n ¼ 8–15; C: n ¼ 9).
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and proliferation of media-derived mural smooth muscle cells.42
Increased lesion volume in castrated mice following wire-injury, but
not following ligation, is consistent with evidence that the influence of
androgens is dependent on the type of lesion.20 Endothelial denudation
is one of the major differences between the wire injury and ligation injury
models. Androgens promote endothelial proliferation and migration
in vitro43 and improve angiogenesis in vivo following ischaemic
injury.44,45 It is possible, therefore, that endothelial regeneration follow-
ing wire injury was impaired by systemic androgen deprivation, thus
favouring formation of lesions. In addition, blocking AR signalling
improves self-renewal and migration of bone marrow-derived
stem cells46 which may promote lesion formation following wire
injury. The well-recognized androgen/AR mediated immune-
suppression47 may also modulate adventitial inflammation and subse-
quent neointima formation and could explain the increased lesion
volume following castration.
Following arterial injury, vascular AR ablation had very little impact in
neointima formation. Deletion of AR from the endothelium increased
lesion volume following arterial ligation, but it was notable that
no similar increase was detected in mice with double knockout of AR
in EC and SMC. This may suggest that deletion of AR in the smooth
muscle opposes the effect of deletion from the endothelium. However,
given the variability of the data in the VE-ARKO following ligation, it
seems more likely that this result is an anomaly, and that, as proposed,
AR in the vascular EC and SMC does not contribute to regulation of
neointimal lesion formation. Excluding a role for the EC and SMC AR
suggests that any influence of androgens on neointimal lesion formation
may be mediated by AR-independent mechanisms, or by conversion to
oestrogen by aromatization either systemically or locally in the vascular
wall, or by AR expressed in other cell types in the vascular wall. It should
be noted, however, that AR expression in the vasculature is not
restricted to EC and SMC. In healthy arteries, cells bearing strong AR ex-
pression were shown to be present in the adventitia, while the popula-
tion of AR-positive adventitial cells was increased in injured arteries. It
was notable that expression of AR in the adventitia of injured arteries
was dramatically reduced following castration. However, the identity
of these AR positive cells and their pathophysiological function
require further investigation. Interestingly, androgens were recently
reported to increase ischaemia-induced angiogenesis, indicating a
direct association between androgen and ECs.43,44 Our VE-ARKO
mice will be a useful tool to address the question whether endothelial
AR truly regulates endothelial function or behaviour using endothelial-
specific models.
The use of vascular selective ARKO mice has shown that AR in the ar-
terial wall have little role in regulating androgen-dependent neointimal
lesion formation. These results suggest that any protective effects of
Figure 6 Castration increases neointimal lesion formation following wire injury but not following arterial ligation. In arteries subjected to either (A)
wire-induced injury or (B) ligation, neointimal lesion distribution (i) and neointimal volume (ii) were determined by OPT. Maximal cross-sectional narrow-
ing (iii) wasmeasured in serial sections stainedwith Masson’s trichrome. PanelsA(i) andB(i) showmean neointimal lesion volumes foreachgroup; errorbars
have been omitted for clarity. Panels A(ii & iii) and B(ii & iii) show individual data points from each animal in the group with lines and error bars indicating
mean+ SEM. *P, 0.05, by Student’s t-test (A: n ¼ 8–10; B: n ¼ 6–8 ).
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androgens in atherosclerosis are likely to be mediated by conversion of
testosterone to oestrogens, by effects on classical cardiovascular risk
factors such as cholesterol, or by AR outside the vascular wall. Future
investigations should try to determine whether androgens inhibit ath-
erosclerosis through direct modulation of non-vascular AR or following
conversion to oestrogens.
Supplementary material
Supplementary material is available at Cardiovascular Research online.
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